Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bofumustine
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Bofumustine is a **nitrosourea compound** with antitumor activity. It belongs to the class of **alkylating agents** that interfere with DNA replication and division in tumor cells[9]. As a nitrosourea, bofumustine works by alkylating DNA and RNA, leading to crosslinking of DNA strands and subsequent disruption of cancer cell proliferation. The drug was developed as part of the nitrosourea family of chemotherapeutic agents, which are known for their ability to cross the blood-brain barrier. Bofumustine has been investigated for its anticancer properties in various malignancies.
- Other names
- Bofumustine
02
Targets
DNA
Beyond the preview
Go deeper on bofumustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bofumustine.